Search research articles
Contact Us
Filters
Showing results (71-80 of 120) with videos related to
Page
of 12
Sort By:
Journal of Andrology
|
March 1, 1989
Microrecanalization after vasectomy in man
M J Freund, J E Weidmann, M Goldstein, et al.
International Journal of Cancer
|
May 1, 1994
HLA restriction and T-cell-receptor V beta gene expression of cytotoxic T lymphocytes reactive with human squamous-cell carcinoma of the head and neck
S Yasumura, E Weidmann, H Hirabayashi, et al.
The Journal of Biological Chemistry
|
October 26, 2000
The Wilms' tumor gene product (WT1) modulates the response to 1,25-dihydroxyvitamin D3 by induction of the vitamin D receptor
U Maurer, F Jehan, C Englert, et al.
Clinical Endocrinology
|
May 26, 1999
The effects of interleukin-2 treatment on endothelin and the activation of the hypothalamic-pituitary-adrenal axis
C Raab, E Weidmann, A Schmidt, et al.
Leukemia
|
May 3, 2002
The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia
T Karakas, C C Miething, U Maurer, et al.
Cancer Research
|
October 15, 1993
Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes
E Weidmann, T F Logan, S Yasumura, et al.
International Journal of Clinical Pharmacy
|
March 23, 2022
The standards of practice for delivery of polypharmacy and chronic disease medication reviews by general practice clinical pharmacists: a consensus study
Katie Earle-Payne, Paul Forsyth, Chris F Johnson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 25, 2011
Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas
E Weidmann, A Neumann, F Fauth, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 16, 2002
Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma
E Weidmann, S-Z Kim, A Rost, et al.
Cancer
|
September 1, 1993
Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study
L Bergmann, K Fenchel, E Weidmann, et al.
Page
of 12
Search research articles
Search
Showing results (71-80 of 120) with videos related to
Sort By:
Page
of 12
Journal of Andrology
|
March 1, 1989
Microrecanalization after vasectomy in man
M J Freund, J E Weidmann, M Goldstein, et al.
International Journal of Cancer
|
May 1, 1994
HLA restriction and T-cell-receptor V beta gene expression of cytotoxic T lymphocytes reactive with human squamous-cell carcinoma of the head and neck
S Yasumura, E Weidmann, H Hirabayashi, et al.
The Journal of Biological Chemistry
|
October 26, 2000
The Wilms' tumor gene product (WT1) modulates the response to 1,25-dihydroxyvitamin D3 by induction of the vitamin D receptor
U Maurer, F Jehan, C Englert, et al.
Clinical Endocrinology
|
May 26, 1999
The effects of interleukin-2 treatment on endothelin and the activation of the hypothalamic-pituitary-adrenal axis
C Raab, E Weidmann, A Schmidt, et al.
Leukemia
|
May 3, 2002
The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia
T Karakas, C C Miething, U Maurer, et al.
Cancer Research
|
October 15, 1993
Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes
E Weidmann, T F Logan, S Yasumura, et al.
International Journal of Clinical Pharmacy
|
March 23, 2022
The standards of practice for delivery of polypharmacy and chronic disease medication reviews by general practice clinical pharmacists: a consensus study
Katie Earle-Payne, Paul Forsyth, Chris F Johnson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 25, 2011
Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas
E Weidmann, A Neumann, F Fauth, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 16, 2002
Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma
E Weidmann, S-Z Kim, A Rost, et al.
Cancer
|
September 1, 1993
Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study
L Bergmann, K Fenchel, E Weidmann, et al.
Page
of 12